Lyell Immunopharma reports Q3 results [Seeking Alpha]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Seeking Alpha
More on Lyell Immunopharma Lyell Immunopharma buys exclusive global rights to colorectal cancer drug Seeking Alpha's Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lyell Immunopharma
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 GlobeNewswire
- Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
LYEL
Analyst Actions
- 11/24/25 - HC Wainwright
LYEL
Sec Filings
- 12/5/25 - Form S-3
- 12/5/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- LYEL's page on the SEC website